Aquila Solutions, LLC Partners with Evofem, Inc. to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive

After partnering with Aquila's eCTD publishing support, Evofem, Inc. announced that they have submitted a large New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of Amphora as a contraceptive vaginal gel for women

Jul 13, 2015, 07:00 ET from Aquila Solutions, LLC

ATLANTA, July 13, 2015 /PRNewswire/ -- Publishing partner Aquila Solutions, LLC would like to congratulate sponsor Evofem, Inc. on the successful submission of their new drug application to the U.S. Food and Drug Administration (FDA) for approval of Amphora as a contraceptive vaginal gel for women.

Amphora, a non-hormonal vaginal gel, approved by the FDA as a lubricant, has been investigated as a contraceptive and is also being investigated for microbicidal properties.

Josh Boutwell, President and CEO of Aquila Solutions said, "We are pleased to have worked alongside Evofem during the publishing and submission phase of Amphora's development." Adding, "We wish Evofem the best of luck on their future endeavors, and look forward to working together again."

Founded in 2010, Aquila Solutions, LLC is a worldwide leader in eCTD (electronic regulatory publishing services). The company offers a wide range of products and services specializing in Regulatory Operations and eCTD publishing. Aquila has created thousands of sequences and offers same day delivery on small sequences.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

 

 

SOURCE Aquila Solutions, LLC